Sunovion and Novartis Enter Agreement to Market 3 COPD Treatments in US
Sunovion Pharmaceuticals and Novartis have entered a commercialization agreement for three drugs approved by the U.S. Food and Drug Administration (FDA) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6…